Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muhammad Abdul-Ghani

Showing results (11-20 of 98) with videos related to

Pageof 10
Sort By:
Diabetes|October 20, 2020
Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose ToleranceAmalia Gastaldelli, Muhammad Abdul Ghani, Ralph A DeFronzo
Nature Reviews. Nephrology|March 26, 2026
Insulin resistance and hyperinsulinaemia in kidney disease: mechanisms and metabolic effectsHussein Zaitoon, Muhammad Abdul-Ghani, Ralph A DeFronzo
Nature Reviews. Nephrology|December 13, 2016
Renal, metabolic and cardiovascular considerations of SGLT2 inhibitionRalph A DeFronzo, Luke Norton, Muhammad Abdul-Ghani
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 10, 2011
Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunctionJohn Armato, Ralph A DeFronzo, Muhammad Abdul-Ghani, et al.
Diabetes, Obesity & Metabolism|April 13, 2026
Insulin Sensitive Patients With Impaired Glucose Tolerance: Physiologic and Metabolic Characterization (STOP DIABETES)John Armato, Ralph A DeFronzo, Muhammad Abdul-Ghani, et al.
The Journal of Clinical Endocrinology and Metabolism|August 7, 2024
Pre-Prediabetes: Insulin Resistance Is Associated With Cardiometabolic Risk in Nonobese Patients (STOP DIABETES)John Armato, Ralph A DeFronzo, Muhammad Abdul-Ghani, et al.
Diabetes & Vascular Disease Research|February 2, 2019
Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetesRalph A DeFronzo, Silvio Inzucchi, Muhammad Abdul-Ghani, et al.
Diabetes Spectrum : a Publication of the American Diabetes Association|August 7, 2015
Novel Agents for the Treatment of Type 2 DiabetesRalph A DeFronzo, Curtis L Triplitt, Muhammad Abdul-Ghani, et al.
Diabetes Care|May 22, 2016
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME StudyMuhammad Abdul-Ghani, Stefano Del Prato, Robert Chilton, et al.
The Journal of Clinical Endocrinology and Metabolism|February 22, 2019
Mild Physiologic Hyperglycemia Induces Hepatic Insulin Resistance in Healthy Normal Glucose-Tolerant ParticipantsDevjit Tripathy, Aurora Merovci, Rita Basu, et al.
Pageof 10

Showing results (11-20 of 98) with videos related to

Sort By:
Pageof 10
Diabetes|October 20, 2020
Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose ToleranceAmalia Gastaldelli, Muhammad Abdul Ghani, Ralph A DeFronzo
Nature Reviews. Nephrology|March 26, 2026
Insulin resistance and hyperinsulinaemia in kidney disease: mechanisms and metabolic effectsHussein Zaitoon, Muhammad Abdul-Ghani, Ralph A DeFronzo
Nature Reviews. Nephrology|December 13, 2016
Renal, metabolic and cardiovascular considerations of SGLT2 inhibitionRalph A DeFronzo, Luke Norton, Muhammad Abdul-Ghani
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 10, 2011
Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunctionJohn Armato, Ralph A DeFronzo, Muhammad Abdul-Ghani, et al.
Diabetes, Obesity & Metabolism|April 13, 2026
Insulin Sensitive Patients With Impaired Glucose Tolerance: Physiologic and Metabolic Characterization (STOP DIABETES)John Armato, Ralph A DeFronzo, Muhammad Abdul-Ghani, et al.
The Journal of Clinical Endocrinology and Metabolism|August 7, 2024
Pre-Prediabetes: Insulin Resistance Is Associated With Cardiometabolic Risk in Nonobese Patients (STOP DIABETES)John Armato, Ralph A DeFronzo, Muhammad Abdul-Ghani, et al.
Diabetes & Vascular Disease Research|February 2, 2019
Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetesRalph A DeFronzo, Silvio Inzucchi, Muhammad Abdul-Ghani, et al.
Diabetes Spectrum : a Publication of the American Diabetes Association|August 7, 2015
Novel Agents for the Treatment of Type 2 DiabetesRalph A DeFronzo, Curtis L Triplitt, Muhammad Abdul-Ghani, et al.
Diabetes Care|May 22, 2016
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME StudyMuhammad Abdul-Ghani, Stefano Del Prato, Robert Chilton, et al.
The Journal of Clinical Endocrinology and Metabolism|February 22, 2019
Mild Physiologic Hyperglycemia Induces Hepatic Insulin Resistance in Healthy Normal Glucose-Tolerant ParticipantsDevjit Tripathy, Aurora Merovci, Rita Basu, et al.
Pageof 10